SAB Biotherapeutics (SABS) Stock Price, Quote, News & History | Benzinga

SPY776.19−0.25%QQQ740.39−0.76%BTC/USD83,451.10+2.10%DIA517.11−0.15%GLD381.39−0.20%TLT78.38+0.42%

SAB Biotherapeutics Inc (SABS) Stock Price, Quote, News & History

SABSNASDAQ

Trade with Public

Trade with Public

$2.83

0.0050.18%

Last update: Oct 13, 11:30 AM

$2.93

0.103.53%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.85

Close

-

Volume / Avg.

75.44K / 498.11K

Day Range

$2.82 - $2.84

52 Wk Range

2.10 - 5.15

Market Cap

$257.49M

P/E Ratio

11.77

Dividend Yield

-

Exchange

NASDAQ

RSI

31

Short Interest

4.87%

Days to Cover

4.99

Recent SAB Biotherapeutics, Inc. News

Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst ratings page. Barclays, Wells Fargo, Piper Sandler, Leerink Partners, Truist Securities, and Citigroup updated their price targets and ratings for AVA, LEN, GMED, SABS, PDM, and PAYX. Evercore ISI Group and Truist Securities also raised their price targets and ratings for LEN and DDOG.

Avi Kapoor

This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, and initiations. Analysts view QUIK stock positively.

Avi Kapoor

Why Is SAB BIO Stock Trading Lower On Tuesday?

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.

Vandana Singh

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Avi Kapoor

Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-53.94M

Investing Cash Flow (TTM)

-202.11M

Financing Cash Flow (TTM)

260.93M

Free Cash Flow (TTM)

-57.44M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

4.89M

Analyst Trends and Forecast

4

May

4

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$172.27M

PE Ratio (TTM)

11.77

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.20

Earnings Yield % (TTM)

8.50%

Earnings Yield % (FWD)

-21.24%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.36

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

$127.44K

Total Cash

$8.27M

Debt to Equity

0.02

Issuance of Debt (TTM)

$127.44K

Repayment of Debt (TTM)

-$148.41K